CorMatrix ECM Study: To Identify Inflammatory Markers Following CABG With/Without ECM (CorMatrix)
CorMatrix ECM Study: To Identify Inflammatory Markers Following CABG With/Without CorMatrix's Extra Cellular Matrix (ECM)
Sponsor: Corvivo Cardiovascular, Inc.
Terminated
This trial was terminated. No reason was provided.
Other Coronary Artery Disease trials with similar outcome
Listed as NCT01535807, this NA trial focuses on Coronary Artery Disease and remains terminated or withdrawn. Sponsored by Corvivo Cardiovascular, Inc., it has been updated 9 times since 2012, reflecting limited change activity. This study contributes longitudinal data to the cardiovascular research landscape.
Status Flow
Change History
9 versions recorded-
Jan 2026 — Present [monthly]
Terminated NA
-
Sep 2024 — Jan 2026 [monthly]
Terminated NA
-
Jul 2024 — Sep 2024 [monthly]
Terminated NA
-
Dec 2022 — Jul 2024 [monthly]
Terminated NA
-
Feb 2022 — Dec 2022 [monthly]
Terminated NA
Status: Unknown Status → Terminated
▶ Show 4 earlier versions
-
Jan 2021 — Feb 2022 [monthly]
Unknown Status NA
-
Jun 2018 — Jan 2021 [monthly]
Unknown Status NA
-
Feb 2018 — Jun 2018 [monthly]
Unknown Status NA
Status: Active Not Recruiting → Unknown Status
-
Jan 2017 — Feb 2018 [monthly]
Active Not Recruiting NA
First recorded
Jan 2012
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Corvivo Cardiovascular, Inc.
- Inova Health Care Services
For direct contact, visit the study record on ClinicalTrials.gov .